Home News Clinical Trials

Clinical Trials

.MP Baijayant “Jay” Panda Asks India to Embrace Modern Science in Support of Humane...

MP Baijayant "Jay" Panda Asks India to Embrace Modern Science in Support of Humane Society International's Campaign to End Animal Testing for Cosmetics

New Delhi, Delhi, India, Thursday, March 14, 2013 -- (Business Wire India) -- Member of Parliament Baijayant "Jay" Panda calls on the government to end animal testing for cosmetics in India - giving a boost to a campaign that is spreading around the world. Panda, an elected representative from Kendrapara, Odisha, wrote letters to the Ministers of Health and Family Welfare, Environment and Forests, and Consumer Affairs, supporting Humane Society International/India's call to end to cosmetic testing on animals as soon as possible.

Clinical Research is a big challenge in current regulatory scenarios in India.

Dr. Devesh Kumar, MD Founder and Managing Director Innovate Research Pvt. Limited     Entering into service industry especially Clinical Research is a big challenge in current regulatory scenarios in India.   Dr. Devesh and team has taken...

Dr. Atul NC Peters recognized as ‘International Surgeon of Excellence’ by Surgical Review Corporation...

Patients who have undergone Bariatric surgery walk the ramp in a unique fashion show New Delhi, 29thApril, 2015 :Dr Atul NC Peters, Director, Bariatric, Metabolic and Minimum Access Surgery, Fortis Hospital, Shalimar Bagh was adjudged the...

High R&D spending drags Biocon Q3 net

In the process of listing its subsidiary Syngene Bengaluru, Jan 30, 2015 - Higher spending on R&D has brought down Biocon’s net profit for the third quarter. The Bengaluru-based biotechnology company posted a net profit of Rs.91 crore for the December 2014...

Sanofi unit begins trials of rotavirus vaccine

Hyderabad, October 15, 2014 - Shantha Biotechnics, an arm of vaccine maker Sanofi Pasteur, has commenced phase-II clinical trial of its investigational rotavirus vaccine. The trial is designed to show non-inferiority against a currently-licensed vaccine with the use of three...

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

New Novartis heart failure drug cuts risk by a fifth

Barcelona, September 01, 2014 - A new heart failure drug from Novartis cut the risk of both cardiovascular death and hospitalisation by a fifth in a keenly awaited study, boosting hopes for a product that is seen as a...

World’s first dengue vaccine likely by 2015: Sanofi

The company said the vaccine gives a 95.5% protection against severe dengue and an 80.3% reduction in the risk of hospitalisation. New Delhi, November 2014 - As India deals with increasing number of dengue cases, pharma major Sanofi on Tuesday said...

The 15th edition of Bangalore INDIA BIO 2015 to focus on startups, clinical trials&rare...

The 15th edition of Bangalore INDIA BIO is scheduled from February 9-11th 2015 Bangalore, Feb 05, 2015: 15th edition of the India’s biggest and most sought after Biotech event "Bangalore INDIA BIO 2015" will comm ence on February 9 to...

AstraZeneca and Lilly to test new cancer drug combination

London, June 01, 2015 AstraZeneca and Eli Lilly are to combine two of their cancer drugs in a new clinical trial against solid tumors in the latest sign that such cocktails may be the way forward in fighting the disease. AstraZeneca’s...